Anhui Anke Biotechnology (Group) Co., Ltd. (ANHUI ANKE BIOTECHNOLOGY(GROUP)) Aktie

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits. In addition, it offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, essential liquids, and mouthwash; and sybthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, the company provides autosomal, sex chromosome, and other kits; paternity testing, tumor biological immunotherapy technology, and DNA testing services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab, an anti-VFDF product; ANKEBIO anti-PD1; and anti-covid19 products. The company was founded in 2000 and is based in Hefei, China.